The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.
Biovian Oy announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland on July 26, 2023. The new facility plans to include house cutting-edge equipment and advanced technologies to support Advanced Therapy Medicinal Products (ATMP), such as adenoviral and adeno-associated viral (AAV) therapies.
According to the press release, it will feature dedicated Class A to D cleanroom areas for bulk drug substances and final drug product manufacture. Additionally, the expanded facility will follow current good manufacturing practices (cGMP) and fulfill both EU and US GMP requirements.
The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025. Further, the investment hopes to create 100 job opportunities in the region.
Source: Biovian
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.